tiprankstipranks
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Price & Analysis

Compare
2,053 Followers

BMRN Stock Chart & Stats


---

Bulls Say, Bears Say

Bulls Say
EarningsBMRN beat expectations by reporting total sales of $747M in 4Q24 which is higher than projections of $712/$708M that represents a +16% YoY growth.
Financial PerformanceThe company continues to track toward $4B revenue in 2027 with a greater than 25% CAGR for the Voxzogo franchise.
Product ApprovalVoxzogo's approval for young patients and strong commercial infrastructure provide a competitive advantage.
Bears Say
Investor InterestThere were no updates on the BD front, and it is thought that activity here will be needed to meaningfully invigorate investor interest.
Operational ExpensesHigher-than-expected SG&A expense was explained by a bad debt reserve and higher Voxzogo commercialization costs associated with the ERP implementation.
---

Financials

Quarterly

Ownership Overview

0.95%36.73%0.42%39.39%
0.42% Other Institutional Investors
39.39% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

BMRN FAQ

What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $60.63 and its highest was $94.85 in the past 12 months.
    What is BioMarin Pharmaceutical’s market cap?
    BioMarin Pharmaceutical’s market cap is $13.49B.
      When is BioMarin Pharmaceutical’s upcoming earnings report date?
      BioMarin Pharmaceutical’s upcoming earnings report date is Apr 23, 2025 which is in 21 days.
        How were BioMarin Pharmaceutical’s earnings last quarter?
        BioMarin Pharmaceutical released its earnings results on Feb 19, 2025. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.534 by $0.106.
          Is BioMarin Pharmaceutical overvalued?
          According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does BioMarin Pharmaceutical pay dividends?
            BioMarin Pharmaceutical does not currently pay dividends.
            What is BioMarin Pharmaceutical’s EPS estimate?
            BioMarin Pharmaceutical’s EPS estimate is 0.7.
              How many shares outstanding does BioMarin Pharmaceutical have?
              BioMarin Pharmaceutical has 190,777,050 shares outstanding.
                What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
                BioMarin Pharmaceutical reported an EPS of $0.64 in its last earnings report, beating expectations of $0.534. Following the earnings report the stock price went up 4.755%.
                  Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
                  Currently, no hedge funds are holding shares in BMRN
                  ---

                  Company Description

                  BioMarin Pharmaceutical

                  BioMarin Pharmaceutical Inc. is a biotechnology company that specializes in developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. Primarily operating in the healthcare sector, BioMarin focuses on rare genetic disorders, leveraging its expertise in enzyme replacement therapies, gene therapies, and small molecule drugs. Its core products include treatments for conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS), and other rare diseases, with its therapies aiming to address unmet medical needs.
                  ---

                  BMRN Company Deck

                  ---

                  BMRN Earnings Call

                  Q4 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The earnings call for BioMarin highlighted strong financial growth and strategic advancements, particularly in VOXZOGO's expansion and enzyme therapy sales. Despite some expected reductions in growth rates for certain enzyme products and increased SG&A expenses, the overall sentiment remains positive due to strong revenue growth, expanded profitability, and promising future outlook.Read More>
                  ---

                  BMRN Revenue Breakdown

                  28.98%28.98%19.42%17.37%12.56%21.66%
                  28.98% VIMIZIM
                  19.42% VOXZOGO
                  17.37% NAGLAZYME
                  12.56% PALYNZIQ
                  21.66% Other
                  tipranks
                  ---

                  BMRN Stock 12 Month Forecast

                  Average Price Target

                  $99.39
                  ▲(46.29% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"62":"$62","95":"$95","128":"$128","78.5":"$78.5","111.5":"$111.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":127,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$127.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$99.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[62,78.5,95,111.5,128],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.16,75.45538461538462,79.75076923076922,84.04615384615384,88.34153846153846,92.63692307692307,96.93230769230769,101.22769230769231,105.52307692307693,109.81846153846153,114.11384615384615,118.40923076923076,122.70461538461538,{"y":127,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.16,73.33153846153846,75.50307692307692,77.67461538461538,79.84615384615384,82.0176923076923,84.18923076923076,86.36076923076922,88.53230769230768,90.70384615384614,92.8753846153846,95.04692307692308,97.21846153846154,{"y":99.39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.16,71.07076923076923,70.98153846153846,70.8923076923077,70.80307692307692,70.71384615384615,70.62461538461538,70.53538461538461,70.44615384615385,70.35692307692308,70.2676923076923,70.17846153846153,70.08923076923077,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":87.14,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.1,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.33,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.13,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.21,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Alnylam Pharma
                  Ionis Pharmaceuticals
                  Regeneron
                  Vertex Pharmaceuticals
                  Ultragenyx Pharmaceutical

                  Best Analysts Covering BMRN

                  1 Year
                  Cory KasimovEvercore ISI
                  1 Year Success Rate
                  23/46 ratings generated profit
                  50%
                  1 Year Average Return
                  -1.90%
                  assigned a buy rating 3 months ago
                  Copying Cory Kasimov's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.90% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis